Business

Business

Pfizer is a research-based global biopharmaceutical company: it discovers, makes, and sells prescription medicines and vaccines, booking $62.6 billion of revenue in 2025 across primary care, specialty care, oncology, and hospital/biosimilars [1] [2]. It clears both universe lines — a NYSE-listed US company at a ~$141 billion market cap. It is not a car maker and, down more than a fifth from its 2024 high and trading near 2.2x sales, not a consensus darling. The framework-relevant tension is durability: every drug is a wasting patent asset, and a 2026–2030 exclusivity cliff is disclosed.

What Pfizer is, in two sentences

Pfizer sells patented and off-patent prescription drugs and vaccines to healthcare systems worldwide — its largest franchises are the blood thinner Eliquis, the Prevnar pneumococcal vaccine family, the Vyndaqel cardiomyopathy family, and the COVID products Comirnaty and Paxlovid [3]. It earns money by discovering or acquiring molecules, winning regulatory approval, and selling them at a premium during a limited period of patent exclusivity, funding an R&D and dealmaking engine that must replace each product as its patent expires.

The company was incorporated in Delaware in 1942 and traces its roots to 1849 [4] — a genuinely long operating history [5]. It runs three operating segments — Biopharma, Pfizer CentreOne (contract manufacturing), and Pfizer Ignite — but Biopharma is the only reportable segment and supplies 98% of revenue [6] [7].

Sources: revenue and net income — FY2025 10-K, Consolidated Statements of Operations [8]; employees (~75,000 at 31 Dec 2025) — Item 1, Our People [9]; market cap ($140.8B) derived from a $24.64 close on 24 Jul 2026 and 5,713M shares (fit_features.market_cap).

The revenue arc — a COVID windfall, then reversion

The last five years are dominated by one event. Total revenues nearly doubled from $41.7 billion in 2020 to a peak of $100.3 billion in 2022 as Comirnaty and Paxlovid scaled, then fell back toward $62.6 billion in 2025 as COVID demand faded [10] [11].

Sources: 2020–2022 — FY2022 10-K, Total Revenues by Geography [12]; 2023–2025 — FY2025 10-K, Total Revenues by Geography [13]. Figures are continuing operations; pre-2020 years are not comparable because Pfizer spun off its Upjohn off-patent unit (Viatris, Nov 2020) and contributed consumer health to a GSK joint venture (2019).

Stripping out COVID, the underlying base is roughly flat-to-growing: management reports 2025 revenue fell 2% headline but rose 6% operationally excluding Comirnaty and Paxlovid [14]. The 2025 revenue split — $51.7 billion of product sales, $9.3 billion of alliance revenue (largely the BioNTech-partnered Comirnaty), and $1.7 billion of royalties — matters for the yield work in Yield, because the deterministic feature file measures the revenue trajectory on product revenues alone and so understates the COVID peak by the alliance component [15].

Product concentration and segment economics

Revenue is concentrated in a handful of franchises. Twelve products each cleared $1 billion in 2025 and together accounted for 65% of total revenue; Eliquis alone was 13% [16]. The commercial portfolio spans primary care (internal medicine, vaccines, migraine), specialty care, oncology (Ibrance, Xtandi, Padcev and the Seagen antibody-drug-conjugate portfolio), and a hospital/biosimilars book of sterile injectables and biosimilars [17].

Source: FY2025 10-K, Note 17C — Significant Revenues by Product [18].

The economics are high-gross-margin but R&D- and amortization-heavy: 2025 cost of sales ran 25.7% of revenue, R&D was $10.4 billion (17% of revenue), and amortization of acquired intangibles added $4.9 billion [19]. This is an intellectual-property business, not a capital-intensive one — capital expenditure was only $2.6 billion in 2025. The moat, where it exists, is a patent plus the R&D engine that refills the pipeline, not physical assets that are hard to reproduce.

Pfizer also pays a large, long-running dividend — $1.72 per share declared in 2025 [20], its 349th consecutive quarterly payout — and its stated capital-allocation order is to maintain and grow the dividend, reinvest, and repurchase shares only "after de-levering" [21]. At $24.64 that dividend is a ~7.0% yield; the subordination of buybacks to debt paydown is examined in Self-Help.

Geography — and the China sensitivity

Revenue is majority-US. In 2025 the United States generated $37.1 billion (59%) and international operations $25.5 billion (41%) [22].

Source: FY2025 10-K, MD&A — Total Revenues by Geography [23].

On China (the framework's S1 sensitivity), exposure is real but modest and quantified: China was Pfizer's largest market outside the US in 2025 at 5% of total revenue (about $3.1 billion), up from 4% in 2024 [24]. The exposure is a headwind, not a tailwind: management flags China's volume-based-procurement (VBP) and quality-consistency (QCE) generic programs as sources of continuing price cuts and volume loss for off-patent products [25]. Because Pfizer is a US-incorporated, NYSE-listed company, the China listing exclusion does not apply; this is a demand/pricing sensitivity of limited size.

A different concentration sits on the customer side: Pfizer's three largest US wholesaler customers — McKesson, Cencora, and Cardinal Health — represented 25%, 16%, and 13% of total revenue respectively in 2025 (54% combined), the standard US pharmaceutical distribution structure rather than end-demand concentration [26].

Market structure — the P1 raw material

Global pharmaceuticals is best described as a research-based oligopoly at the top, sitting above a large generic and biosimilar tier, with intense regulation on both entry and price. Pfizer's own filing calls its markets "intensely competitive and highly regulated," and names three distinct competitor types: other worldwide research-based firms, smaller focused research companies, and generic/biosimilar manufacturers [27]. No single company dominates the industry; competition runs franchise by franchise, and Pfizer's rivals name it directly in their filings.

Regulatory entry barriers are high — for a molecule, and time-limited. Bringing a drug to market requires FDA or EMA approval after years of clinical trials, which no garage startup can shortcut; a patent then grants a temporary monopoly on that molecule. But that same regime hands the franchise back to competition on expiry: once patent or regulatory exclusivity lapses, generic and biosimilar makers — often without large R&D costs — sell near-identical products at much lower prices, and revenue "can substantially decrease… often in a very short period of time" [28]. Pfizer discloses that it expects "a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030," with the rate of erosion accelerating [29]. This is the central durability question the report carries into Durability: the corporate entity is essential and long-lived, but each product is a wasting asset, so year-10 revenue depends on the pipeline and acquisitions replacing the coming cliff — not on a fixed moat.

Named competition, cited to rivals' own filings:

• Moderna identifies Pfizer/BioNTech as its principal COVID-19 vaccine competitor (Spikevax vs Comirnaty) and Pfizer as an RSV rival that reached the US market first [30].
• Merck attacks Pfizer's largest vaccine franchise, Prevnar, from both the adult side (Capvaxive) and the pediatric/adult side (Vaxneuvance), and blames competition for its flat pneumococcal sales [31].
• GSK competes head-to-head in adult RSV (Arexvy vs Pfizer's Abrysvo) and says it holds market-leading US share among older adults [32].

Bristol-Myers Squibb, Johnson & Johnson, and AstraZeneca round out the large-cap research peer set overlapping oncology, immunology, and cardiovascular. The takeaway for the framework: Pfizer is a durable, essential, long-established enterprise in a regulated oligopoly, but its durability rests on continuous product replacement rather than the fixed, capital-heavy, "someone-else-cannot-build-this" moat the system prizes most.

Universe screen

The market-cap figure is the deterministic feature (fit_features.market_cap_usd): a $24.64 close on 24 July 2026 times 5,713 million shares outstanding [33]. The US listing and Delaware incorporation are stated in Item 1 [34].

First-pass exclusion screen

Auto OEM (X1): no. Pfizer makes medicines and vaccines; it is not an automobile manufacturer. No hit.

Consensus-saturated darling (X4): no. Pfizer screens as the opposite of a crowded growth story. It trades at about 2.2x sales ($140.8 billion market cap on $62.6 billion revenue) and roughly 18x trailing GAAP earnings, pays a ~7% dividend, and its chart runs top-left-to-bottom-right — down about 21% from a July 2024 high (and as much as 31% into its April 2025 low) and far below its 2021–2022 COVID-era peak [35]. Consensus is cautious, not euphoric: the sell side models a declining forward FCF profile against the disclosed 2026–2030 patent cliff [36]. The multiple, the yield, and the drawdown all point away from a saturated darling; the anatomy of the decline is developed in Dislocation.

China dependence (S1): flagged and quantified. China is 5% of 2025 revenue (~$3.1 billion) and a pricing headwind, not a listing problem — a limited sensitivity, detailed above [37].

The promotional-CEO (X2) and structural-decline (X3) checks belong to Self-Help and Durability; nothing in the business description settles them here, though the disclosed patent cliff is the fact those tabs must weigh temporary reversion against.